Delving into the Latest Updates on Excel Pharma Studies, Inc. with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Endocrinology and Metabolic Disease

Degradable Molecular Glue

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Degradable Molecular Glue	1

Top 5 Target	Count

CK1α x CRBN x IKZF1 x IKZF3	1

Primary objective: To compare the pharmacokinetic characteristics of a single 52 cm2 granisetron transdermal patch applied on the outer side of the upper arm for 6 consecutive days with oral administration of 1 mg granisetron tablets twice daily for 5 consecutive days in healthy Chinese subjects. Secondary objective: To evaluate the local tolerability and safety of the granisetron transdermal patch.

Start Date15 May 2013

Sponsor / Collaborator

Strakan International Ltd.

[+2]

CTR20131874

/ CompletedPhase 3

评价SOM230长效制剂与奥曲肽长效制剂治疗活动期肢端肥大症安全性及疗效的多中心、随机、双盲临床研究

[Translation] A multicenter, randomized, double-blind clinical study to evaluate the safety and efficacy of SOM230 long-acting preparation and octreotide long-acting preparation in the treatment of active acromegaly

评价SOM230长效制剂与奥曲肽长效制剂治疗活动期肢端肥大症的安全性及疗效

[Translation]

To evaluate the safety and efficacy of SOM230 long-acting preparation and octreotide long-acting preparation in the treatment of active acromegaly

Start Date09 Mar 2009

Sponsor / Collaborator

Excel Pharma Studies, Inc.

[+1]

100 Clinical Results associated with Excel Pharma Studies, Inc.

Login to view more data

0 Patents (Medical) associated with Excel Pharma Studies, Inc.

Login to view more data

1

Literatures (Medical) associated with Excel Pharma Studies, Inc.

01 Jan 2014·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Effect of Isopropanolic Cimicifuga racemosa Extract on Uterine Fibroids in Comparison with Tibolone among Patients of a Recent Randomized, Double Blind, Parallel‐Controlled Study in Chinese Women with Menopausal Symptoms

Q4 · MEDICINE

ArticleOA

Author: Hu, Lina ; Bai, Wenpei ; Jiao, Chunfeng ; Zhang, Zhonglan ; Wang, Shuyu ; Xi, Sisi ; Liske, Eckehard ; Geng, Li ; Zepelin, Hans-Heinrich Henneicke-von ; Zheng, Shurong ; Liu, Jianli

Objective. Effect of isopropanolic Cimicifuga racemosa extract (iCR) on uterine fibroid size compared with tibolone. Method. The randomized, double‐blind, controlled study in China enrolled 244 patients aged 40–60 years with menopausal symptoms (Kupperman Menopause Index ≥ 15). The participants were treated with either iCR of 40 mg crude drug/day (N = 122) or tibolone 2.5 mg/day (N = 122) orally for 3 months in 2004. Now, we investigated the subset of all women (N = 62) with at least one uterine fibroid at onset of treatment for the effect of iCR (N = 34) on fibroid size compared with tibolone (N = 28) by transvaginal ultrasonography. Results. The median myoma volume decreased upon iCR by as much as −30% (P = 0.016) but increased upon tibolone by +4.7%. The percentage of volume change, mean diameter change and geometric mean diameter change of the iCR group compared to tibolone were statistically significant (P = 0.016, 0.021, 0.016 respectively). Conclusion. Our results suggest that iCR (Remifemin) is a valid herbal medicinal product in patients with uterine myomas as it provides adequate relief from menopausal symptoms and inhibits growth of the myomas in contrast to tibolone.

100 Deals associated with Excel Pharma Studies, Inc.

Login to view more data

100 Translational Medicine associated with Excel Pharma Studies, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lenalidomide ( CK1α x CRBN x IKZF1 x IKZF3 )	Multiple Myeloma More	Phase 3
Orteronel ( CYP17A1 )	Metastatic castration-resistant prostate cancer More	Pending
Pasireotide Diaspartate ( SSTR1 x SSTR2 x SSTR3 x SSTR5 )	Acromegaly More	Pending
Granisetron ( HTR3 )	Nausea More	Pending